No Routine Surveillance Required for Resolved Hepatitis B with Immunity
In patients with resolved hepatitis B infection and documented immunity (HBsAg negative, anti-HBc positive, anti-HBs positive), routine long-term follow-up and surveillance laboratory testing is NOT required under normal circumstances.
Key Serological Profile
Your patient has the classic serological pattern of resolved HBV infection:
- HBsAg negative (no active infection)
- Anti-HBc IgG positive (past exposure)
- Anti-HBs positive (protective immunity)
This profile indicates complete viral clearance with protective antibody response, representing the ideal outcome of HBV infection.
When Surveillance IS NOT Needed
For immunocompetent patients with this serological profile:
- No routine HBV DNA monitoring is required
- No periodic HBsAg testing is necessary
- No ALT surveillance for HBV purposes
- No HCC surveillance based on HBV status alone
The major guidelines 1, 2 focus surveillance recommendations exclusively on HBsAg-positive patients (chronic infection), not those with resolved infection and immunity.
Critical Exception: Immunosuppression Risk
The only scenario requiring surveillance is if the patient will undergo immunosuppressive therapy. This is the most important caveat:
High-Risk Immunosuppression Requiring Prophylaxis
Patients with resolved HBV (HBsAg negative/anti-HBc positive) need antiviral prophylaxis when receiving 2:
- Anti-CD20 therapy (rituximab, obinutuzumab)
- Hematopoietic stem cell transplantation
- High-dose corticosteroids with chemotherapy
- Combination immunosuppressive regimens 3
Anti-HBs Status Matters for Risk Stratification
Research demonstrates that anti-HBs negativity significantly increases reactivation risk during immunosuppression 4, 3:
- Anti-HBs positive patients: ~5% reactivation risk
- Anti-HBs negative patients (isolated anti-HBc): ~14% reactivation risk
- Odds ratio 0.21 for reactivation with anti-HBs present 4
Since your patient is anti-HBs positive, they have lower risk, but prophylaxis is still recommended for high-risk immunosuppression 2, 5.
Monitoring Strategy During Immunosuppression
If immunosuppressive therapy is planned 2:
Option 1 (Preferred for high-risk therapy):
- Start prophylactic tenofovir (TDF or TAF) or entecavir before immunosuppression
- Continue for at least 12-18 months after completing therapy
- Extend to 18 months for B-cell depleting agents
Option 2 (Pre-emptive monitoring):
- Monitor HBV DNA every 3 months during and after immunosuppression
- Check HBsAg as alternative marker
- Start antivirals immediately if HBV DNA becomes detectable
- ALT monitoring alone is inadequate (lags behind viral reactivation by 4-12 weeks)
Occult HBV Infection Consideration
While approximately 2-10% of patients with resolved HBV may have occult infection (detectable HBV DNA despite negative HBsAg) 6, this does not warrant routine surveillance in immunocompetent individuals. The clinical significance emerges only during immunosuppression or in blood donation contexts.
Common Pitfalls to Avoid
Don't confuse resolved infection with chronic inactive infection: HBsAg-negative/anti-HBc-positive/anti-HBs-positive patients are fundamentally different from HBsAg-positive patients who require ongoing surveillance 1, 2
Don't order unnecessary HCC surveillance: HCC screening is indicated for HBsAg-positive patients with specific risk factors (cirrhosis, age >40-50, family history), not for resolved infection 1
Don't forget to screen before immunosuppression: The critical error is failing to identify resolved HBV before starting immunosuppressive therapy 5
Don't assume all anti-HBc positive patients are the same: Those with anti-HBs have significantly better protection than isolated anti-HBc positive patients 4, 3
Bottom Line
For your immunocompetent patient with resolved HBV and documented anti-HBs positivity, no routine follow-up or surveillance is needed. Document this serological status in their chart and ensure it's checked before any future immunosuppressive therapy. The presence of anti-HBs provides reassurance of protective immunity, though reactivation prophylaxis would still be indicated for high-risk immunosuppression scenarios.